Tyrphostin AG213  (Synonyms: AG213)

Tyrphostin AG213 (AG213) is an inhibitor of epidermal growth factor receptor (EGFR) protein tyrosine kinase (IC₅₀=0.85 μM). Tyrphostin AG213 inhibits tyrosine kinase activity IC₅₀=2.4 μM) and topoisomerase II (IC₁₀₀=50 μM). Tyrphostin AG213 can induce nonapoptotic cell programmed death in tumor cells^[1][2][3].

Tyrphostin AG213 (25 μM, 50 μM, and 75 μM; 24 h, 48 h, and 96 h) increases wound closure time in human umbilical vein endothelial cell (HUVEC) monolayer^[1].
Tyrphostin AG213 (100 μM; 1 h) interferes with HUVEC focal adhesion and stress fiber formation^[1].
Tyrphostin AG213 (100 μM; 24 h) inhibits adherence-related tyrosine phosphorylation of pp125FAK in HUVEC^[1].
Tyrphostin AG213 (10 μM; 24 h) inhibits tyrosine kinase activity, and (4.55-455 mM; 24-72 h) inhibits HT-29 cell viability dose- and time-dependently^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

220.25

C₁₀H₈N₂O₂S

122520-86-9

S=C(N)/C(C#N)=C/C1=CC=C(O)C(O)=C1.[(E)]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Romer LH, et al. Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells. Mol Biol Cell. 1994 Mar;5(3):349-61.  [Content Brief]